BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

A/C Diagnostics Unit of AntiCancer Receives FDA Clearance for a Portable Homocysteine Test


10/20/2008 7:19:26 AM

SAN DIEGO--(BUSINESS WIRE)--The A/C Diagnostics unit of AntiCancer, Inc., has received FDA clearance to market its A/C Portable Enzymatic Homocysteine Assay on the A/C Diagnostic Reader. The new homocysteine assay uses a genetically-engineered enzyme specific for homocysteine. The assay will be able to serve the need for widespread testing for homocysteine, a risk factor for cardiovascular and other diseases. “The simplicity of this test enables an economical price structure for the test kit. This gives us the possibility for gaining a significant share of the homocysteine test market,” said Yuying Tan, Product Manager and lead researcher for the A/C Portable Enzymatic Homocysteine Assay.

The A/C Portable Enzymatic Homocysteine Assay can measure total homocysteine (tHCY) in a 3-step single-enzyme assay with a small portable fluorescence reader, the A/C Diagnostics Reader, and can assist diagnosis and treatment of hyperhomocysteinemia, a risk factor for cardiovascular disease and other diseases. This test is precise and can be carried out in a small lab, a doctor’s office or a pharmacy as it requires small amounts of blood, even from a finger prick. The assay kit is only for in vitro use.

A/C Diagnostics is a unit of AntiCancer, Inc., developing diagnostic tests based on specific recombinant enzymes. Other tests based on recombinant enzymes also being developed by A/C Diagnostics include vitamin B6 and the amino acid cysteine, both associated with cardiovascular and other diseases.

AntiCancer, Inc., founded in 1984 and located in San Diego, is also developing new drugs for cancer based on genetic engineering and targeting cancer specific metabolic defects. The company markets clinically-relevant imageable mouse models of metastatic cancer for cancer drug discovery and evaluation using fluorescent proteins for imaging. The company is also developing gene therapy for cancer and for diseases of the hair follicle.

Contact:

AntiCancer, Inc. Charlene M. Cooper, 858-654-2555 Fax: 858-268-4175 all@anticancer.com

Source: AntiCancer, Inc.


Read at BioSpace.com


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->